European Archives - Page 791 of 995 - European Medical Journal

RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis

Tel-Aviv, Israel, Raleigh, USA, 14 June, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”)…

Acarix Receives First Commercial Order for CADScor®System for Early Detection of Coronary Artery Disease from Danish Hospital

Malmö, Sweden, 13 June, 2017 – Acarix AB (publ) (“Acarix” or the “Company”) today announced that Herning Hospital has placed the first commercial order…

New LEADER Analysis Shows Victoza® Reduces Cardiovascular Risk in People With Type 2 Diabetes Regardless of Severe Hypoglycaemia Events

New LEADER analysis shows Victoza® reduces cardiovascular risk in people with Type 2 Diabetes regardless of severe hypoglycaemia events.

PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers

PharmaMar announces encouraging results in clinical trials of Lurbinectedin in endometrial and breast cancers. Find out more

Humane Resources: Funding Restrictions in Rare Rheumatic Diseases

As any rheumatologist knows, most non-medical individuals don’t really know what ‘rheumatology’ is. Not so much of a bad reputation, as no reputation.

New Biomarker in Renal Replacement Therapy

SURVIVAL in patients undergoing renal replacement therapy could be improved by the utilisation of biomarker measurements, according to the results of a…

Stereotactic Ablative Radiation Therapy: A Better Alternative to Conventional Therapy?

TREATMENT of metastatic kidney cancer using a focussed therapy known as stereotactic ablative radiation has been shown to result in >90% control of…

EMJ

Professor Edwards’ Invitation to Biogen’s Satellite Symposium at EULAR 2017

Video Invitation from Chris Edwards (Professor of Clinical Rheumatology, University of Southampton, UK) to Biogen’s Satellite Symposium at EULAR 2017…

Abiraterone Acetate Plus Prednisone Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival

Beerse, Belgium, 3 June, 2017 – Janssen-Cilag International NV today announced data from the pivotal Phase 3 LATITUDE clinical trial, which showed Zytiga…

Introducing EMJ Hepatology 5.1

United Kingdom, June 08, 2017: Welcome to the latest edition of our EMJ Hepatology eJournal! This issue is jam-packed with the latest hepatological…